Tracer library / [86Y]pepa-pic2
[86Y]pepa-pic2
- Radionuclide
- Y-86 t½ 884.4 min
- Modality
- PET
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- pepa-pic2 chelator platform (rare-earth chelator)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | — | pepa-pic2 | 41324598 2025 J Am Chem Soc Optimization of radiolabeling conditions was conducted using 86YCl3 at pH 5.5, to yield [86Y]Y-mepa-pic2, [86Y]Y-pepa-pic2, and [86Y]Y-pepa2-pic |
Need this precursor?We can point you to suppliers for [86Y]pepa-pic2, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41324598. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41324598: '[86Y]Y-pepa-pic2'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Y-86 is a positron emitter used only for PET imaging. Linked articles: PMID 41324598. Stage set/updated at stage 39 from PMID 41324598: 'Biodistribution studies with Y-86-labeled analogs identified [86Y]Y-pepa-pic2 as the lead scaffold, showing rapid renal clearance, minimal nontarget retention, and high in vivo stability.'.